AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03615716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level Violence Prevention Intervention - Boys
Description: Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
Study NCT03615716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level Violence Prevention Intervention - Caregivers
Description: This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
Study NCT04291482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choosing Health Intervention
Description: The intervention consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention, basic information on healthy eating and behaviour change and tables allowing self-monitoring of weight, physical activity and eating (i.e., brief food diary). The book is non-tailored and it has weekly tasks for the participants to complete during 26 weeks (initial 6 months) to support their weight loss. The intervention group will also receive a series of daily text messages and weekly email messages supporting their weight loss and promoting weight loss maintenance. In phase I (month 0-3), the messages and emails will be generic and factual; in the phase II of the intervention, participants will receive text messages and emails tailored to the strongest predictors of outcomes identified in phase I.
Study NCT04291482 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Choosing Health Control
Description: The control consists of information materials provided at baseline in a form of eBook or a physical book depending on participants preferences. The book includes the rationale for the intervention and basic information on healthy eating and physical activity. The control group will also receive monthly email messages with generic and factual information.
Study NCT00616980 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CD34-positive cells
Study NCT00616980 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline and 5% autologous plasma
Study NCT01329718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood sample collection
Study NCT03873909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit Smoothie
Description: Fruit Smoothie with 150-200 g mamey sapote fruit
Study NCT03873909 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-Free Shake
Description: Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
Study NCT01841450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent
Description: Implantation of one iStent in conjunction with cataract surgery
Study NCT01841450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery alone
Study NCT04655040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 100milligram (mg) tablet taken orally in period 1 and period 2
Study NCT04655040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: 200 milligrams (mg) taken orally once a day(QD) for 8 days
Study NCT03273400 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar Mobilisations
Description: Please see arm (intervention) description
Study NCT02438605 — intervention group
Intervention type: DEVICE
Intervention: Nellix
Study NCT03361865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.
Study NCT01700348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airflosser
Description: Use of Philips Airflosser
Study NCT01700348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Floss
Description: Active Comparator
Study NCT00214032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pycnogenol
Description: pycnogenol 300 mg daily
Study NCT00214032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 3 capsules daily
Study NCT03449537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed casein formula + LGG
Description: Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
Study NCT03361865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.
Study NCT03361865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.
Study NCT03361865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study NCT00176644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Estradiol
Description: application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed.
Study NCT03443310 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound assessment of DVT
Description: Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
Study NCT02395263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yuxintine
Study NCT02395263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuxintine
Study NCT04159649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5Mg Tablet
Description: Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
Study NCT04159649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins
Description: Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
Study NCT04159649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins
Description: Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
Study NCT04159649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial sample in the pretreatment cycle
Description: All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
Study NCT04159649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endometrial sample in the pretreatment cycle
Description: All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
Study NCT03652233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by vein every 14 days for up to 12 months
Study NCT03652233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Taken by mouth daily for up to 12 months
Study NCT01967641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone combination
Description: Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
Study NCT03370575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ethiodized poppyseed oil
Description: Hysterosalpingography using ethiodized poppyseed oil
Study NCT03370575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: the second-generation non-ionic monomer contrast
Description: Hysterosalpingography using the second-generation non-ionic monomer contrast
Study NCT01518231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoiesis stem cell transplantation
Description: Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: aspirin 100mg,qd,po(patients with no fibrillation atrial)
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: warfarin 2\~6mg,qd,po(patients with fibrillation atrial);
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 20mg,qd,po
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: edaravone 30mg,bid,ivgtt.
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Aspirin
Description: aspirin 100mg,qd,po(patients with no fibrillation atrial)
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Warfarin
Description: warfarin 2\~6mg,qd,po(patients with fibrillation atrial)
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atorvastatin
Description: atorvastatin 20mg,qd,po
Study NCT01518231 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Edaravone
Description: edaravone 30mg,bid,ivgtt
Study NCT01253668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Brivanib by mouth daily at a dose of 800mg.
Study NCT01253668 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction
Description: Undergo 1241-cG250 PET/CT imaging (correlative studies)
Study NCT01253668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine I 124 chimeric monoclonal antibody G250
Description: Undergo 124I-cG250 PET/CT imaging (correlative studies)
Study NCT01253668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/computed tomography
Description: Undergo 1241-cG250 PET/CT imaging (correlative studies)
Study NCT01253668 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Protein expression analysis
Description: Correlative studies
Study NCT01253668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry
Description: correlative studies
Study NCT03449537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hypoallergenic formula based on amino-acid based formula
Description: Hypoallergenic formula for cow milk allergy treatment based on amino acids
Study NCT01053637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone/acetaminophen
Description: 0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
Study NCT01053637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar water
Description: An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
Study NCT04878445 — intervention group
Intervention type: PROCEDURE
Intervention: Patients undergoing standard surgery, excess tissue only will be analysed with patient consent.
Description: Lung samples will be obtained from surplus, healthy margin lung tissue resected from patients with suspected or confirmed lung cancer or from resected tissue from lung volume reduction surgery.
Study NCT02357680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU.
Study NCT02905123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Your Drinking
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets.
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone tablets.
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets.
Study NCT00432276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets.
Study NCT00358956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (vandetanib)
Description: 100 mg once daily oral tablet
Study NCT02244346 — intervention group
Intervention type: DRUG
Intervention: Secotex®
Study NCT04496505 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device
Description: is a mask that uses sequences of flashing lights and analogous sounds to trigger a relaxed state in those with intense pain. Pilot studies have so far shown a statistically significantly decrease in pain, anxiety and opiate withdrawal, as well as an increase in heart rate variability. Preliminary data shows a statistically significant decrease in depression symptoms as measured by Patient Health Questionnaire 9 (PHQ-9) scale .
Study NCT04496505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham treatment device was designed to copy the look and feel of thetherapy to a degree that it would be indistinguishable from the true treatment. The sham treatment delivers a series of Audio-Visual Stimulation (AVS) in the form of pulses of light (through closed eyelids) and sound, but that offer no therapeutic effect.
Study NCT01264666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chinese tea flavor liquor
Description: 60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
Study NCT01264666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chinese Meijiao liquor
Study NCT01264666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water control
Study NCT03089671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin B (riboflavin, vitamin B2)
Description: Vitamin B is a natural health product approved as a colouring agent.
Study NCT03089671 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% Dextrose in Water (D5W)
Description: 5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
Study NCT01653860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Brøset anger management model
Description: manualised structured cognitive treatment program 15 weeks (30 hours)
Study NCT01653860 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary group treatment
Description: group treatment 8 weeks (16 hours)
Study NCT04109937 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation therapy
Description: The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
Study NCT03198832 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
Study NCT00126100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF Granulocyte-Colony Stimulating Factor
Description: Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
Study NCT00126100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
Study NCT00655330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan (160mg/day)
Study NCT00655330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (160mg/day)
Study NCT00655330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00655330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: Probucol (750mg/day)
Study NCT02133924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Natalizumab 300mg on days 0 and 14.
Study NCT02133924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
Study NCT01728805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: 1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
Study NCT01728805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Study NCT01644474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
Study NCT01644474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
Study NCT01644474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Alirocumab)
Description: 1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
Study NCT01644474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Ezetimibe)
Description: One capsule orally once daily at approximately the same time of the day with or without food..
Study NCT03763461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
Study NCT03763461 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oxygen Mask
Description: Application of oxygen during conscious sedation
Study NCT00428051 — intervention group
Intervention type: OTHER
Intervention: Surveillance
Description: No study drug, only interventions are blood draws and Chest X-rays
Study NCT01000350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
Study NCT01000350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo x1 lactose tablet
Study NCT03320460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propionate clobetasol gel 0.05%
Description: Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.